George Montgomery

George G. Montgomery

Chief Financial Officer, Neuvogen

Mr. Montgomery currently serves as the Chief Financial Officer of Neuvogen (a next generation therapeutic cancer vaccine company). He is also a founding investor and C-suite executive at Retromer Therapeutics (focused on neurodegenerative disease). Mr. Montgomery also serves as a Senior Advisor to ALTi Tiedemann Global (a leading global independent wealth management platform for global family offices with $68bn AUM). He leads the Audit Committee as part of the Ashvattha Therapeutics Board of Directors.

With over three decades of experience in health care, Mr. Montgomery has deep experience in start-ups (CFO and Board roles), principal investing and investment banking. In leadership roles at JPMorgan H&Q, Cowen and CSFB, he had extensive experience in public and private capital markets, M&A and partnering transactions.

Prior to his current roles, Mr. Montgomery was a managing director at WestRiver Group where he co-led the firm’s health care investments in biotech and digital health and tech enabled services. Prior to WRG, he was a partner at Gurnet Point Capital, a $2bn AUM dedicated global health care fund and served on portfolio Company Boards including Boston Pharmaceuicals and Crossover Health. Prior to Gurnet Point, Mr. Montgomery was Chief Financial Officer of Coherus Biosciences from business plan through the IPO.

Since 2018, Mr. Montgomery has served on the Jackson Laboratory Board and Executive Committee. He also serves on the Yale Cancer Center Advisory Board and Yale Crew Association Board. Mr. Montgomery received his B.A. in Political Science from Yale College and an MBA in Finance from the Wharton School of Business at the University of Pennsylvania.